Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Aktis Oncology, Inc.AKTS · Entity 4711 | Director | July 20, 2026 | July 22, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Aktis Oncology, Inc.
Report date July 20, 2026 · Filed July 22, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2026-07-20 transaction · row 4
4 source rows · reconciled sequenceRow 1 · 2026-07-20 · Exercise / conversion · Acquired 3,506 · Balance 3,506 Row 2 · 2026-07-20 · Exercise / conversion · Acquired 1,350 · Balance 4,856 Row 3 · 2026-07-20 · Sale · Disposed 3,506 · Balance 1,350 F1: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.50 to $24.66, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Row 4 · 2026-07-20 · Sale · Disposed 1,350 · Balance 0 F1: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.50 to $24.66, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.08 · Expires 2030-11-23 | Direct | 0 |
Reported balance
After 2026-07-20 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2026-07-20 · Exercise / conversion · Disposed 3,506 · Balance 0 F2: These options have vested in full. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.91 · Expires 2031-04-14 | Direct | 18,364 |
Reported balance
After 2026-07-20 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2026-07-20 · Exercise / conversion · Disposed 1,350 · Balance 18,364 F2: These options have vested in full. |
Filing footnotes · ownership attribution and instrument terms
F1: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.50 to $24.66, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
F2: These options have vested in full.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 20, 2026 Filed Jul 22, 2026 00:50 UTC | Aktis Oncology, Inc. AKTS · Entity 4711 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,350 | $0.00 Strike: $1.91 | $0.00 |
DisclosureSEC source: 0001193125-26-310991 · ownership.xml · derivative · entry 6 Herrmann Ken · CIK 0002049757 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,364 Underlying: Common Stock · 1,350 shares Expires 2031-04-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: These options have vested in full. Read SEC document |
| July 20, 2026 Filed Jul 22, 2026 00:50 UTC | Aktis Oncology, Inc. AKTS · Entity 4711 | Exercise / conversionStock Option (Right to Buy) · Derivative | 3,506 | $0.00 Strike: $0.08 | $0.00 |
DisclosureSEC source: 0001193125-26-310991 · ownership.xml · derivative · entry 5 Herrmann Ken · CIK 0002049757 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,506 shares Expires 2030-11-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: These options have vested in full. Read SEC document |
| July 20, 2026 Filed Jul 22, 2026 00:50 UTC | Aktis Oncology, Inc. AKTS · Entity 4711 | SaleCommon Stock | 1,350 | $24.56 | $33,158.97 |
DisclosureSEC source: 0001193125-26-310991 · ownership.xml · nonDerivative · entry 4 Herrmann Ken · CIK 0002049757 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.50 to $24.66, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| July 20, 2026 Filed Jul 22, 2026 00:50 UTC | Aktis Oncology, Inc. AKTS · Entity 4711 | SaleCommon Stock | 3,506 | $24.56 | $86,115.07 |
DisclosureSEC source: 0001193125-26-310991 · ownership.xml · nonDerivative · entry 3 Herrmann Ken · CIK 0002049757 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,350 F1 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.50 to $24.66, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| July 20, 2026 Filed Jul 22, 2026 00:50 UTC | Aktis Oncology, Inc. AKTS · Entity 4711 | Exercise / conversionCommon Stock | 1,350 | $1.91 | $2,578.50 |
DisclosureSEC source: 0001193125-26-310991 · ownership.xml · nonDerivative · entry 2 Herrmann Ken · CIK 0002049757 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,856 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 20, 2026 Filed Jul 22, 2026 00:50 UTC | Aktis Oncology, Inc. AKTS · Entity 4711 | Exercise / conversionCommon Stock | 3,506 | $0.08 | $280.48 |
DisclosureSEC source: 0001193125-26-310991 · ownership.xml · nonDerivative · entry 1 Herrmann Ken · CIK 0002049757 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,506 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 17, 2026 Filed Jul 20, 2026 21:34 UTC | Aktis Oncology, Inc. AKTS · Entity 4711 | Exercise / conversionStock Option (Right to Buy) · Derivative | 3,065 | $0.00 Strike: $0.08 | $0.00 |
DisclosureSEC source: 0001193125-26-309115 · ownership.xml · derivative · entry 3 Herrmann Ken · CIK 0002049757 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,506 Underlying: Common Stock · 3,065 shares Expires 2030-11-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: These options have vested in full. Read SEC document |
| July 17, 2026 Filed Jul 20, 2026 21:34 UTC | Aktis Oncology, Inc. AKTS · Entity 4711 | SaleCommon Stock | 3,065 | $25.21 | $77,258.54 |
DisclosureSEC source: 0001193125-26-309115 · ownership.xml · nonDerivative · entry 2 Herrmann Ken · CIK 0002049757 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.00 to $25.4950, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| July 17, 2026 Filed Jul 20, 2026 21:34 UTC | Aktis Oncology, Inc. AKTS · Entity 4711 | Exercise / conversionCommon Stock | 3,065 | $0.08 | $245.20 |
DisclosureSEC source: 0001193125-26-309115 · ownership.xml · nonDerivative · entry 1 Herrmann Ken · CIK 0002049757 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,065 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.